2022
-
03
-
08
點(diǎn)擊次數(shù):
康體生命成立于2016年，為國(guó)家高新技術(shù)企業(yè)，為客戶(hù)提供包括GPCR等靶點(diǎn)蛋白納米抗體藥物開(kāi)發(fā)CRO服務(wù)。公司由長(zhǎng)江學(xué)者杜洋教授領(lǐng)銜，技術(shù)團(tuán)隊(duì)由多位生物醫(yī)藥博士負(fù)責(zé)，組建有哺乳動(dòng)物細(xì)胞、昆蟲(chóng)細(xì)胞、酵母、大腸桿菌等蛋白表達(dá)純化平臺(tái)，納米抗體發(fā)現(xiàn)平臺(tái)，抗體工程平臺(tái)，質(zhì)量分析平臺(tái)等，為客戶(hù)提供納米抗體定制研發(fā)解決方案?？刁w生命擁有2000平米實(shí)驗(yàn)室及各種實(shí)驗(yàn)設(shè)備。納米抗體開(kāi)發(fā)團(tuán)隊(duì)免疫或篩選過(guò)的抗原或靶點(diǎn)包括但不限于Hpv16，Hpv18，Claudin18.2，Lilrb-2，Amyloid A，Procalcitonin，TAC2，PD-1，PD-L1，CTLA4，CD3（epsilon&gamma），Integrin，病毒樣顆粒，AAV，IL-5.PCSK9，KLH偶聯(lián)的各種多肽包括磷酸化多肽及乙?；蚣谆嚯?，KLH-HAKLH-Myc,KLH-Flag,GST,CD7,CD28,CD33,CD38,CD70,CD73,CD79,CD22,CD123,CD167, GRP78，Human RAGE，HSP70，HSP90，ROR1，IGF2R，IGFBP5，GPC3，SARS-CoV-2 S1包括Delta及Omicron RBD蛋白，EBV gHqL，KRAS，CXCL1，GUCY2C，hTPX2，Nectin4，Leptin，F(xiàn)GF R4,VEGFR2,VEGFR3,FAP,CEACAM5,PSMA,PSA,YAP,B7H7,TIGIT,VEGF A,IL-2R,Wnt2, 人載脂蛋白A-1，人載脂蛋白 B， 人血紅蛋白，SERPINA3，人轉(zhuǎn)鐵蛋白，GFP.mCherry，鼠lgG，兔lgG及許多客戶(hù)提供的不知名的靶點(diǎn)蛋白。除了蛋白抗原外，康體生命科技有限公司也用細(xì)胞，滅活病毒，病毒樣顆粒，細(xì)胞膜碎片等對(duì)羊駝進(jìn)行免疫。AlpaLife is a biotechnology company in China founded by scientists with strong background in antibody production and G-protein coupled receptors (GPCRs) drug discovery. Now we exclusively engage in development and production of customized well-performed and high-quality Alpaca nanobodies (single-domain antibodies or VHHs) for cytoplasmic proteins and membrane proteins (especially GPCRs) and related products for life-sciences, biotechnology and bio-medical research. Nanobodies are the emerging novel tools for both basic scientific research and clinical therapeutics. They have unique properties including small size (~15 KD), high affinity, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration, which enables a wide range of applications such as affinity capture reagents, crystallization chaperones, target imaging and immunomodulation, biosensors, in vivo imaging, antivenom therapy and anti-infective agents.AlpaLife carries out nanobodies development through both Immune and non-Immune naïve and synthetic libraries. We have been working with multiple top pharmaceutical companies in China. Cooperated with laboratories in more than ten countries including U.S., Germany, South Korea, Thailand etc. Trying to provide the products with the best service, quality and reliability to the scientific community worldwide. Now we already have successful cases including human C-Reactive Protein nanobodies and 2019-Sars-Cov2 spike protein nanobodies, and we are collaborating with the Chinese University of Hong Kong in Shen Zhen for GPCR targeted nanobodies development. We offer one-stop solution from antigen preparation to selected nanobody purification and evolution. With extensive experience in custom single domain antibody development, we are ready to help simplify and accelerate your research by novel nanobodies.